Mubritinib Completed Phase 1 Trials for Renal Neoplasms / Breast Neoplasms / Pancreatic Neoplasms / Ovarian Neoplasms / Lung Neoplasm Treatment

IndicationsStatusPurposePhase
CompletedTreatment1
clinicaltrials.gov IdentifierTitleDrugs
NCT00034281Safety and Tolerability Study of TAK-165 in Subjects With Tumors Expressing HER2